Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Company Overview

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics. This LNP platform underpins the company’s RNAi assets and has been the foundation for collaborations with other biopharmaceutical organizations seeking efficient delivery systems for mRNA and RNA-based medicines. Arbutus’ focus on innovative delivery solutions complements its antiviral drug discovery capabilities, positioning it at the forefront of HBV research and development.

Founded through the merger of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus maintains dual operations in Warminster, Pennsylvania, and Vancouver, British Columbia. The company’s leadership team combines experience in virology, lipid chemistry and pharmaceutical development, supporting strategic alliances with academic institutions and contract research organizations worldwide. Arbutus continues to engage with global regulatory authorities to advance its clinical trials and seeks partnerships to broaden the reach of its potential HBV therapies.

Key Stats

• Today's Range: $4.40 to $4.51
• 50-Day Range: $3.13 to $4.90
• 52-Week Range: $2.70 to $5.10
• Volume: 394,251 shs
• Average Volume: 953,089 shs
• Market Capitalization: $859.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Arbutus Biopharma Stock Analysis - MarketRank™

Arbutus Biopharma scored higher than 25% of companies evaluated by MarketBeat, and ranked 745th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Buy

Consensus Rating

Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Arbutus Biopharma has a consensus price target of $5.00, representing about 11.5% upside from its current price of $4.49.

Amount of Analyst Coverage

Arbutus Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arbutus Biopharma is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arbutus Biopharma is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arbutus Biopharma has a P/B Ratio of 8.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.91% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Arbutus Biopharma has recently decreased by 15.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arbutus Biopharma does not currently pay a dividend.

Dividend Growth

Arbutus Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.91% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Arbutus Biopharma has recently decreased by 15.67%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

19 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 111% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABUS Stock Analysis - Frequently Asked Questions

How have ABUS shares performed this year?

Arbutus Biopharma's stock was trading at $3.27 at the beginning of 2025. Since then, ABUS stock has increased by 37.2% and is now trading at $4.4850.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corporation (NASDAQ:ABUS) issued its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The biopharmaceutical company earned $10.74 million during the quarter, compared to analysts' expectations of $2.21 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 59.28% and a negative net margin of 352.24%.

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's top institutional investors include Two Seas Capital LP (5.45%), Geode Capital Management LLC (1.90%), BlackBarn Capital Partners LP (1.36%) and Adage Capital Partners GP L.L.C. (1.34%).
View institutional ownership trends.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/24/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABUS
• CIK: 1447028
• Web: www.arbutusbio.com
• Phone: (267) 469-0914
• Fax: 604-419-3201
• Employees: 90
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Arbutus Biopharma: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +12.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.92 million
• Net Margins: -352.24%
• Pretax Margin: -351.92%
• Return on Equity: -59.28%
• Return on Assets: -44.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.53
• Quick Ratio: 20.53

Sales & Book Value

• Annual Sales: $6.17 million
• Price / Sales: 138.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 8.75

Miscellaneous

• Outstanding Shares: 191,700,000
• Free Float: 152,784,000
• Market Cap: $854.98 million
• Optionable: Optionable
• Beta: 1.01